雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

THE ROLE OF IMMUNE RNA IN THE IMMUNOTHERAPY OF MALIGNANT BRAIN TUMOR Osamu Nakamura 1 , Kintomo Takakura 1 1Department of Neurosurgery, University of Tokyo pp.333-339
Published Date 1982/4/1
DOI https://doi.org/10.11477/mf.1406204919
  • Abstract
  • Look Inside

At present, nonspecific immunotherapy using BCG or Picibanil is popular as an immunotherapy for malignant brain tumor. On the other hand, specific immunotherapy using lymphocytes which play an important role in the passive transmission of tumor immunity is also performed. But this therapy has some disadvantage such as the problem of blocking factor or histocompatibility. To com-pensate for this disadvantage, specific immunothera-py using the chemical mediater, immune RNA, extracted from immunized lymphocytes has started. We extracted immune RNA from the spleen of immunized rat using phenol and SDS, and observed the effect of normal lymphocytes preincubated with immune RNA in vitro and in vivo experi-ments. In in vitro experiment, following results were obtained.

(1) Normal lymphocytes incubated with im-mune RNA revealed a significant cytotoxicity andthis effect was disappeared by the pretreatment of immune RNA with RNase.

(2) Cytotoxic effect of immune RNA seemed to be a tumor specific response.

(3) Not only syngeneic RNA, but also xeno-geneic RNA were effective. In addition to these results, we decided the optimal condition in which immune RNA transferred the cell mediated cytoto-xicity to normal lymphocytes.

Next, we tried the purification of immune RNA by way of sucrose density gradient centrifugation method and oligo (dT) cellulose affinity chromato-graphy method. Active fraction of immune RNA was contained in 8-16 S fraction and in poly (A) containing fraction. As in vivo experiment, we injected immune RNA incubated lymphocytes in-travenously to brain tumor-bearing rats and observed for death daily. In this experiments, significant prolongation of mean survival time was recognized in the group treated with immune RNA.

We now consider the clinical application of im-mune RNA for malignant brain tumor by the following method : immune RNA is obtained from the lymphocytes of sheep which has immunized with patient's tumor cells. And then patient's own lymphocytes strengthened by incubation with immune RNA is injected intratumorally by way of Ommaya's reservoir. To do this therapy safely and effectively, further purification of immune RNA and solution of its physiochemical character-istics will be necessary.


Copyright © 1982, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 2185-405X 印刷版ISSN 0006-8969 医学書院

関連文献

もっと見る

文献を共有